Sophia C. Kamran, MD, is a Radiation Oncologist at the Massachusetts General Hospital and an Associate Professor of Radiation Oncology at Harvard Medical School. She is an Associate Member of the Broad Institute of MIT and Harvard. In her clinic, Dr. Kamran specializes in the treatment of genitourinary cancers. Her research interests focus on the application of computational genomic approaches to characterize tumor evolution to treatment and understand mechanisms of toxicity and resistance to radiation and chemoradiation. Her long-term goal is to use these approaches to guide the design of clinical trials of high-precision radiation therapy to enable personalized approaches to delivery of radiation therapy for patients with genitourinary cancers. Her research has received distinctions from the American Society for Radiation Oncology (Basic/Translational Science Research Award) as well as the MGH Department of Radiation Oncology William Shipley Research Award. Dr. Kamran was nationally recognized as a "40 Under 40 in Cancer Rising Stars and Emerging Leaders" by the Lynx Group/McGivney Global Advisors in 2018. She is the recipient of the MGH Center for Diversity & Inclusion’s Physician Scientist Development Award for her work on single nucleotide polymorphisms as predictors of toxicity following radiation therapy for prostate cancer, the first awardee in the Department of Radiation Oncology. She is also the recipient of the inaugural Loeffler Team Science Seed Grant for her translational work in immunoradiotherapy. Dr. Kamran has several professional membership affiliations with organizations such as the American Society for Radiation Oncology, the American Urological Association, the Accreditation Council for Graduate Medical Education, the Radiation Research Society, the American Society for Clinical Oncology, the American Board of Radiology, the American Association for Cancer Research, the Massachusetts General Hospital Cancer Center Equity Council, and the Massachusetts Prostate Cancer Coalition. She is a recipient of a 2023 Harvard Medical School Harold Amos Faculty Diversity Award, an award given to individuals who have demonstrated a significant commitment to enhancing diversity and inclusion at HMS and its teaching hospitals. Dr. Kamran was selected as part of the first class of MGH Anne Klibanski Visiting Scholars, an award for female faculty who have demonstrated exceptional promise as leaders in their field. She was the 2024 Co-Chair of the Renal & Rare Tumors Track for the ASCO Genitourinary Cancers Symposium and the Organizing Chair for the 2023 Coffey-Holden Prostate Cancer Academy Meeting, sponsored by the Prostate Cancer Foundation. She is on the NCI P01 Massachusetts General Hospital Internal Steering Committee, serves on the Editorial Board for Clinical Genitourinary Cancer, and is a GU Associate Section Editor for Practical Radiation Oncology. Her work has been published in many high-quality journals, including The New England Journal of Medicine, Clinical Cancer Research, JAMA Oncology, European Urology, and others. 

Dr. Kamran holds a bachelor’s degree in Biological Engineering from the Massachusetts Institute of Technology, which she attended as a Gates Millennium Scholar. She received her medical degree cum laude from Harvard Medical School. During her medical training, she completed a Howard Hughes Medical Student Research Fellowship. She completed a transitional year internship at Memorial Sloan Kettering Cancer Center and residency training at the Harvard Radiation Oncology Program.